FROM HEMATOCRIT NORMALIZATION TO BIOLOGICAL REMISSION: OUTCOMES OF ROPEGINTERFERON ALFA-2B IN POLYCYTHEMIA VERA AT AN ITALIAN TERTIARY CARE CENTER (SIE 2026) - Oct 6, 2026 - Abstract #SP124; "Background. RopegIFN is confirmed to be well tolerated and effective, with high CHR rates and significant VAF re- duction, supporting a potential disease-modifying effect. Identification of early predictors of response/resistance may guide more personalized treatment choices, particularly in the second-line setting (RopegIFN vs ruxolitinib)."
Clinical • Cardiovascular • Endocrine Disorders • Grave's Disease • Polycythemia Vera • JAK2
|
|
D. Sannipoli1; Mh. Parrinello1,2; P. Ronchi3; F. Ciceri1,2; F. Lunghi4
|